Race Oncology Ltd
ASX:RAC

Watchlist Manager
Race Oncology Ltd Logo
Race Oncology Ltd
ASX:RAC
Watchlist
Price: 2.77 AUD -2.12% Market Closed
Market Cap: 494.8m AUD

Net Margin
Race Oncology Ltd

-607.2%
Current
-4 584%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-607.2%
=
Net Income
-4.8m
/
Revenue
788.4k

Net Margin Across Competitors

No Stocks Found

Race Oncology Ltd
Glance View

Market Cap
481.3m AUD
Industry
Biotechnology

Race Oncology Ltd. is a precision oncology company, with the phase 2/3 cancer drug, Bisantrene, which is a potent small molecule inhibitor of the Fatso (FTO) protein. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-07-13. Bisantrene is a small molecule inhibitor of the fat mass and obesity associated (FTO) protein. The firm is targeting the use of Bisantrene in melanoma and clear cell renal cell carcinoma (kidney cancer), both frequent FTO-driven cancers. Race also has clinical data for the use of Bisantrene in Acute Myeloid Leukaemia (AML), Breast and Ovarian cancers.

RAC Intrinsic Value
0.42 AUD
Overvaluation 85%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-607.2%
=
Net Income
-4.8m
/
Revenue
788.4k
What is the Net Margin of Race Oncology Ltd?

Based on Race Oncology Ltd's most recent financial statements, the company has Net Margin of -607.2%.

Back to Top